Compare CIM & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | CDNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 2.6B |
| IPO Year | 2007 | 2007 |
| Metric | CIM | CDNA |
|---|---|---|
| Price | $11.21 | $56.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $15.25 | ★ $28.00 |
| AVG Volume (30 Days) | 922.0K | ★ 1.0M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 10.92% | N/A |
| EPS Growth | ★ 56.36 | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $1.62 | $16.01 |
| Revenue Next Year | $2.48 | $11.31 |
| P/E Ratio | ★ N/A | $26.52 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $10.84 | $13.95 |
| 52 Week High | $14.18 | $56.85 |
| Indicator | CIM | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 69.63 |
| Support Level | N/A | $45.74 |
| Resistance Level | $11.69 | N/A |
| Average True Range (ATR) | 0.18 | 1.91 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 39.64 | 86.71 |
Chimera Investment Corporation is an internally managed REIT whose principal business objective is to provide attractive risk-adjusted returns and distributable income through investment performance linked to mortgage credit fundamentals. Through its mortgage lending, investment management, and advisory services platforms, the Company operates as a fully integrated mortgage business that originates, manages, and invests in a diversified range of mortgage assets. The Company invests, directly or indirectly, generally on a levered basis across a spectrum of mortgage assets, including residential mortgage loans, Non-Agency RMBS, Agency RMBS, Agency CMBS, MSRs, business purpose and investor loans, including RTLs, and other real estate-related assets.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.